Serglycin is an intracellular proteoglycan in hematopoietic cells. It
has been studied in normal and tumor hematopoietic cell, so it was
suggested to have an important role in immunity and cancers as leukemia.
The challenge to make a diagnosis for
acute leukemia and to
differentiate between myeloid or lymphoblastic leukemia, is the reason
we go to assay concentration of serglyc in normal people and
patient with acute myeloid leukemia and acute lymphoblastic leukemia
from children and adult at hematology department in the
main hospitals in Damascus ( Pediatric’shopital, Almouasat and Al
asaad hospital) before beginning any kind of treatment and studying
the relation with white blood cells count. We found clear difference
between the concentration in patient with acute leukemia and normal
people. There was a high level of this marker in paint with
AML in contrast with ALL patients. We found a relation between
concentration of serglycin and the count of white blood cells.
Gene regulation by microRNAs (miRNAs) is one of the most important regulatory
networks which control normal hematopoiesis. Disturbances in miRNAs levels lead to
proliferation diseases including leukemogenesis. MicroRNAs is a major topic of many
ca
ncer researches performed to discover noninvasive biomarkers used for diagnosis,
prognosis, and optimization of clinical decision.
This study, the first to be performed in Syria, aimed at monitoring miR-155 levels
compared to a normalizer gene RNU6-2 by quantitative reverse transcriptase -PCR (qRTPCR)
in a sample of newly diagnosed untreated AML patients at several hospitals in
Damascus in comparison with healthy controls. Changes in miR-155 gene expression
levels were calculated in patients and controls using the 2-ΔCt method.
The most important finding was the association of low and very high miR-155 levels
with poor prognosis reflected in failure to accomplish complete remission and high
mortality. In addition, high miR-155 levels were associated with M4 AML subtype,
although with large variance among patients. We hope our preliminary study pave the road
for many future research studies related to the applicability of microRNAs in supporting
diagnosis, predicting prognosis, and enhancing the personalized therapies which deal with
patients as individual cases.
In the present study, we measured DNMT3A levels, the
methylation enzyme, in blood samples from Syrian AML patients
and normal individuals using real-time quantitative polymerase
chain reaction, in order to determine the roles of DNMT3A in the
development of leukemia.
